Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Yuto HattoriTasuku FujiwaraHiroki HagimotoHidetoshi KokubunShiori MurataNoriyuki MakitaYohei AbeMasashi KubotaYoichiro TohiNaofumi TsutsumiNoboru ShibasakiKoji InoueMutsushi KawakitaToshinari YamasakiPublished in: International journal of urology : official journal of the Japanese Urological Association (2024)
Neoadjuvant ddGC demonstrated good tolerability, efficacy, and safety, suggesting its potential as a treatment option for MIBC.